Compare · MENS vs NVO
MENS vs NVO
Side-by-side comparison of Jyong Biotech Ltd. (MENS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MENS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $228.39B, about 1341.1x MENS ($170.3M).
- Over the past year, MENS is down 87.0% and NVO is up 3.1% - NVO leads by 90.1 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 1 for MENS).
- NVO has more recent analyst coverage (25 ratings vs 0 for MENS).
- Company
- Jyong Biotech Ltd.
- Novo Nordisk A/S
- Price
- $2.33+0.87%
- $51.58+1.25%
- Market cap
- $170.3M
- $228.39B
- 1M return
- +5.91%
- +6.72%
- 1Y return
- -87.03%
- +3.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 1
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MENS
- Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
- Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
- Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
- Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
- SEC Form 20-F filed by Jyong Biotech Ltd.
- SEC Form NT 20-F filed by Jyong Biotech Ltd.
- SEC Form 3 filed by new insider Zhang Wei (Vivi)
- SEC Form 3 filed by new insider Kuo Fu-Feng
- SEC Form 3 filed by new insider Hsu Ming Tsan
- SEC Form 3 filed by new insider Hsu Feng-Lin
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S